In the last three months, 5 analysts have published ratings on Moderna (NASDAQ:MRNA), offering a diverse range of perspectives from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $113.8, a high estimate of $142.00, and a low estimate of $86.00. Observing a 44.97% increase, the current average has risen from the previous average price target of $78.50.

Understanding Analyst Ratings: A...